<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872998</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #111321</org_study_id>
    <nct_id>NCT04872998</nct_id>
  </id_info>
  <brief_title>Vascular Dysfunction During Physical Inactivity</brief_title>
  <official_title>Vascular Dysfunction During Physical Inactivity: Role of Oxidative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah Center for Clinical and Translational Science (CCTS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged periods of reduced activity are associated with decreased vascular function and&#xD;
      muscle atrophy. Physical inactivity due to a sedentary lifestyle or acute hospitalization is&#xD;
      also associated with impaired recovery, hospital readmission, and increased mortality. Older&#xD;
      adults are a particularly vulnerable population as functional (vascular and skeletal muscle&#xD;
      mitochondrial dysfunction) and structural deficits (loss in muscle mass leading to a&#xD;
      reduction in strength) are a consequence of the aging process. The combination of inactivity&#xD;
      and aging poses an added health threat to these individuals by accelerating the negative&#xD;
      impact on vascular and skeletal muscle function and dysfunction. The underlying factors&#xD;
      leading to vascular and skeletal muscle dysfunction are unknown, but have been linked to&#xD;
      increases in oxidative stress. Additionally, there is a lack of understanding of how vascular&#xD;
      function is impacted by inactivity in humans and how these changes are related to skeletal&#xD;
      muscle function. It is the goal of this study to investigate the mechanisms that contribute&#xD;
      to disuse muscle atrophy and vascular dysfunction in order to diminish their negative impact,&#xD;
      and preserve vascular and skeletal muscle function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery vascular function</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Flow rate of brachial artery measured by flow-mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Popliteal artery vascular function</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Flow rate of popliteal artery measured by flow-mediated dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg microvascular function</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Flow rate of leg microvasculature assessed by passive leg movement and measured by flow-mediated dilation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Aging</condition>
  <condition>Vascular Endothelium</condition>
  <condition>Skeletal Muscle</condition>
  <arm_group>
    <arm_group_label>Reduced Activity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduction of daily step count by 70% for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Step Count Reduction</intervention_name>
    <description>Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor</description>
    <arm_group_label>Reduced Activity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who have recently undergone surgery or injury requiring inactivity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac abnormalities considered exclusionary by the study physician (congestive heart&#xD;
             failure, coronary artery disease, right-to-left shunt)&#xD;
&#xD;
          -  Uncontrolled endocrine or metabolic disease&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 45 mL/min/1.73 m^2 or evidence of kidney disease or&#xD;
             failure&#xD;
&#xD;
          -  Vascular disease or risk factors of peripheral atherosclerosis&#xD;
&#xD;
          -  Risk of deep vein thrombosis including family history of thrombophilia, pulmonary&#xD;
             emboli, deep vein thrombosis&#xD;
&#xD;
          -  Use of anticoagulant therapy&#xD;
&#xD;
          -  Elevated systolic pressure &gt; 180 or a diastolic blood pressure &gt; 110&#xD;
&#xD;
          -  Implanted electronic devices such as pacemakers, infusion pumps, stimulators&#xD;
&#xD;
          -  Cancer or history of successfully treated cancer (less than 1 year) other than basal&#xD;
             cell carcinoma&#xD;
&#xD;
          -  Currently on a weight-loss diet or body mass index &gt; 35 kg/m^2&#xD;
&#xD;
          -  Inability to abstain from smoking for duration of study&#xD;
&#xD;
          -  History of &gt; 20 pack per year smoking&#xD;
&#xD;
          -  Positive for human immunodeficiency virus, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Recent anabolic or corticosteroids use (within 3 months)&#xD;
&#xD;
          -  Subjects with hemoglobin or hematocrit lower than accepted lab values&#xD;
&#xD;
          -  Agitation/aggression disorder&#xD;
&#xD;
          -  History of stroke with motor disability&#xD;
&#xD;
          -  Recent history (&lt; 12 months) of gastrointestinal bleed&#xD;
&#xD;
          -  Depression diagnosis&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Liver disease (AST/ALT 2 times above the normal limit, hyperbilirubinemia)&#xD;
&#xD;
          -  Respiratory disease (acute upper respiratory infection, history of chronic lung&#xD;
             disease with resting oxygen saturation &lt; 97% on room air)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel D Trinity, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center Building</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Joel Trinity</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Reduced Activity</keyword>
  <keyword>Muscular Atrophy</keyword>
  <keyword>Vascular Dysfunction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

